R Vyas, MD of Dishman Pharma said the company is looking at making some drastic changes to improve the EBDITA margins in Carbogen Amcis following the appointment of Nick Green as president of the company's CRAM activities.
Money Control
Wednesday 5 August 2009
Dishman plans Carbogen Amcis changes
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment